Update in mortality in GH-treated patients

During GH therapy for 2.3-9.6 years,male adult-onset GH-deficient patients with a diagnosis of a nonfunctioning adenoma have no increased all-cause mortality.However,women with adult-onset GH deficiency(GHD)are still at slightly higher risk.This general improvement in mortality is due to a more contemporary regimen of cardiovascular drugs,a refinement of surgical procedures,besides the introduction of GH therapy improved hormone replacement regimens with lowered glucocorticoid replacement,updated approaches of sex steroids for women,and less use of cranial radiotherapy.The underlying disease is the most important predictor for mortality:eg,a craniopharyngioma,malignant causes of hypopituitarism,previous Cushing's disease,and the presence of diabetes insipidus/

During GH therapy for 2.3-9.6 years, male adult-onset GH-deficient patients with a diagnosis of a nonfunctioning adenoma have no increased all-cause mortality. However, women with adult-onset GH deficiency （GHD） are still at slightly higher risk. This general improvement in mortality is due to a more contemporary regimen of cardiovascular drugs, a refinement of surgical procedures, besides the introduction of GH therapy improved hormone replacement regimens with lowered glucocorticoid replacement, updated approaches of sex steroids for women, and less use of cranial radiotherapy. The underlying disease is the most important predictor for mortality：